Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis

Joint Bone Spine

Volumn 73, Issue 4, 2006, Pages 433-441

  Fautrel, Bruno ^a   Constantin, Arnaud ^b   Morel, Jacques ^c   Vittecoq, Olivier ^d   Cantagrel, Alain ^b   Combe, Bernard ^c   Dougados, Maxime ^e   Le Loët, Xavier ^d   Mariette, Xavier ^f   Pham, Thao ^g   Puéchal, Xavier ^h   Sibilia, Jean ⁱ   Soubrier, Martin ^j   Ravaud, Philippe ^k  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d Rouen Hospital   (France)

^e Cochin Teaching Hospital ^*  (France)

^f BICÊTRE HOSPITAL   (France)

^g Rheumatology Department   (France)

^h CENTRE HOSPITALIER DU MANS   (France)

ⁱ HÔPITAL DE HAUTEPIERRE   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k BICHAT HOSPITAL   (France)

more..

Author keywords

Clinical practice; Disease modifying antirheumatic drugs; Recommendations; Rheumatoid arthritis; TNFalpha antagonists; Treatment

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FOLLOW UP; FRANCE; HUMAN; INFLAMMATION; JOINT RADIOGRAPHY; MEDICAL PRACTICE; MEDICAL SOCIETY; PATIENT MONITORING; PATIENT SELECTION; POPULATION RESEARCH; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; STANDARDIZATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; METABOLISM; PRACTICE GUIDELINE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FRANCE; HUMANS; PRACTICE GUIDELINES; RHEUMATOLOGY; SOCIETIES, MEDICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745810609     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.04.001     Document Type: Article

References (88)

1. Pincus T., Sokka T., and Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 52 (2005) 1009-1019
2. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
3. Goekoop-Ruiterman Y.P.M., De Vries-Bouwstra J.K., van Zeben D., Kerstens P.J.S.M., Hazes J.M.W., Zwinderman A.H., et al. Treatment strategies in early rheumatoid arthritis: clinical and radiological outcomes after 2 year follow-up in the BeSt study. Arthritis Rheum. 50 (2004) L4
4. Le Loet X., Berthelot J.M., Cantagrel A., Combe B., De Bandt M., Fautrel B., et al. Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann. Rheum. Dis. 65 (2006) 45-50
5. Emery P., Breedveld F.C., Dougados M., Kalden J.R., Schiff M.H., and Smolen J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann. Rheum. Dis. 61 (2002) 290-297
6. Pham T., Gossec L., Fautrel B., Combe B., Flipo R.M., Goupille P., et al. Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72 (2005) 222-228
7. Gossec L., Fautrel B., Pham T., Combe B., Flipo R.M., Goupille P., et al. Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72 (2005) 229-234
8. Fautrel B., Pham T., Gossec L., Combe B., Flipo R.M., Goupille P., et al. Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 72 (2005) 163-170
9. Combe B., and Landewé R. EULAR recommendations for management of early arthritis (Abs SP0060). Ann. Rheum. Dis. 64 (2005) 19
10. Blumenauer B., Judd M., Wells G., Burls A., Cranney A., Hochberg M., et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. (2002) (CD003785)
11. Blumenauer B., Judd M., Cranney A., Burls A., Coyle D., Hochberg M., et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. (2003) (CD004525)
12. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann. Rheum. Dis. 61 (2002) ii70-ii73
13. Le Loet X., Lequerre T., and Vittecoq O. Rheumatoid arthritis in 2005: which patients should receive TNFalpha antagonists and when? A point of view. Joint Bone Spine 72 (2005) 447-450
14. Jobanputra P., Barton P., Bryan S., and Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 6 (2002) 1-110
15. Emery P., Reginster J.Y., Appelboom T., Breedveld F.C., Edelmann E., Kekow J., et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 40 (2001) 699-702
16. Salvarani C., Olivieri I., Cantini F., Marchesoni A., Punzi L., Scarpa R., et al. Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society. Reumatismo 56 (2004) 133-134 (136-8)
17. Ledingham J., and Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44 (2005) 157-163
18. Durieux P., Ravaud P., Chaix C., and Durand-Zaleski I. La formation médicale continue améliore-t-elle le comportement des médecins ?. Presse Med. 28 (1999) 468-472 [Does continuing medical education improve the way physicians conduct their practice?]
19. Anaes Les recommandations pour la pratique clinique. Bases méthodologiques pour leur réalisation en France. Paris : Agence nationale d'accréditation et d'évaluation en santé, 1999.
20. Collaboration A.G.R.E.E. AGREE instrument (2001), Appraisal of Guidelines for Research and Evaluation, London
21. Shekelle P.G., Woolf S.H., Eccles M., and Grimshaw J. Clinical guidelines: developing guidelines. BMJ 318 (1999) 593-596
22. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
23. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41 (1998) 1552-1563
24. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) vs placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
25. Kavanaugh A., St Clair E.W., McCune W.J., Braakman T., and Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. 27 (2000) 841-850
26. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343 (2000) 1594-1602
27. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50 (2004) 1051-1065
28. Breedveld F.C., Emery P., Keystone E., Patel K., Furst D.E., Kalden J.R., et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 63 (2004) 149-155
29. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
30. Durez P., Van den Bosch F., Corluy L., Veys E.M., De Clerck L., Peretz A., et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 44 (2005) 465-468
31. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337 (1997) 141-147
32. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130 (1999) 478-486
33. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340 (1999) 253-259
34. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1586-1593
35. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
36. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
37. Keystone E.C., Schiff M.H., Kremer J.M., Kafka S., Lovy M., DeVries T., et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 50 (2004) 353-363
38. den Broeder A., van de Putte L., Rau R., Schattenkirchner M., Van Riel P., Sander O., et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. 29 (2002) 2288-2298
39. van de Putte L.B., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L., et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann. Rheum. Dis. 62 (2003) 1168-1177
40. Weisman M.H., Moreland L.W., Furst D.E., Weinblatt M.E., Keystone E.C., Paulus H.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther. 25 (2003) 1700-1721
41. Rau R., Simianer S., van Riel P.L., van de Putte L.B., Kruger K., Schattenkirchner M., et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand. J. Rheumatol. 33 (2004) 145-153
42. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 (2003) 35-45
43. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30 (2003) 2563-2571
44. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63 (2004) 508-516
45. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50 (2004) 1400-1411
46. Breedveld F., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., Perez J.L., et al. Early treatment of Rheumatoid Arthritis (RA) with adalimumab (HUMIRA) plus methotrexate vs. adalimumab alone vs. methotrexate alone: the PREMIER study. Arthritis Rheum. 50 (2004) L5
47. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann. Rheum. Dis. 63 Suppl 2 (2004) ii2-ii12
48. Genovese M.C., Cohen S., Moreland L., Lium D., Robbins S., Newmark R., et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50 (2004) 1412-1419
49. Fransen J., Moens H.B., Speyer I., and van Riel P.L. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann. Rheum. Dis. 64 (2005) 1294-1298
50. van Riel P.L., van Gestel A.M., and van de Putte L.B. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br. J. Rheumatol. 35 Suppl 2 (1996) 4-7
51. del Rincon I., DH O.L., Haas R.W., and Escalante A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum. 50 (2004) 3813-3822
52. Strand V., and Simon L.S. Low dose glucocorticoids in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (2003) S186-S190
53. Leeb B.F., Andel I., Sautner J., Nothnagl T., and Rintelen B. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford) 43 (2004) 1504-1507
54. Gardiner P.V., Bell A.L., Taggart A.J., Wright G., Kee F., Smyth A., et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann. Rheum. Dis. 64 (2005) 506-507
55. Capell H.A., Murphy E.A., and Hunter J.A. Rheumatoid arthritis: workload and outcome over 10 years. Q. J. Med. 79 (1991) 461-476
56. Ingeman-Nielsen M., Halskov O., Hansen T.M., Halberg P., Stage P., and Lorenzen I. Clinical synovitis and radiological lesions in rheumatoid arthritis. A prospective study of 25 patients during treatment with remission-inducing drugs. Scand. J. Rheumatol. 12 (1983) 237-240
57. Maravic M., Bologna C., Daures J.P., Jorgensen C., Combe B., and Sany J. Radiologic progression in early rheumatoid arthritis treated with methotrexate. J. Rheumatol. 26 (1999) 262-267
58. Molenaar E.T., Voskuyl A.E., Dinant H.J., Bezemer P.D., Boers M., and Dijkmans B.A. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 50 (2004) 36-42
59. Mulherin D., Fitzgerald O., and Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br. J. Rheumatol. 35 (1996) 1263-1268
60. Sany J., Kaliski S., Couret M., Cuchacovich M., and Daures J.P. Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis. J. Rheumatol. 17 (1990) 1636-1641
61. Scott D.L., Grindulis K.A., Struthers G.R., Coulton B.L., Popert A.J., and Bacon P.A. Progression of radiological changes in rheumatoid arthritis. Ann. Rheum. Dis. 43 (1984) 8-17
62. Pham T., Claudepierre P., Deprez X., Fautrel B., Goupille P., Hilliquin P., et al. Anti-TNF alpha therapy and safety monitoring: clinical tool guide elaborated by the Club Rhumatismes et Inflammation. Joint Bone Spine 72 (2005) S1-S58
63. Hochberg M.C., Tracy J.K., Hawkins-Holt M., and Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii13-ii16
64. Flendrie M., Creemers M.C., Welsing P.M., den Broeder A.A., and van Riel P.L. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii30-ii33
65. Godinho F., Godfrin B., El Mahou S., Navaux F., Zabraniecki L., and Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. 22 (2004) 328-330
66. Cannon G.W., Holden W.L., Juhaeri J., Dai W., Scarazzini L., and Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J. Rheumatol. 31 (2004) 1906-1911
67. Hansen K.E., Cush J., Singhal A., Cooley D.A., Cohen S., Patel S.R., et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. 51 (2004) 228-232
68. Kiely P.D., and Johnson D.M. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 41 (2002) 631-637
69. Perdriger A.L., Combe B., Kuntz J.L., Brocq O., Terki K., Le Loet X., et al. A French multicenter retrospective study on the efficacy and safety of infliximab in association with DMARDs other than methotrexate. Arthritis Rheum. 48 (2003) S620
70. Mariette X.L., Bijlsma J.W.J., Herold M., Eiselstein J., Spencer-Green G.T., and Kupper H. Adalimumab (HUMIRA) is as effective when used in combination with other DMARDs as with methotrexate in treating rheumatoid arthritis: the ReAct study. Arthritis Rheum. 50 (2004) S183
71. Ferraccioli G.F., Assaloni R., Di Poi E., Gremese E., De Marchi G., and Fabris M. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. Rheumatology (Oxford) 41 (2002) 1109-1112
72. Temekonidis T.I., Georgiadis A.N., Alamanos Y., Bougias D.V., Voulgari P.V., and Drosos A.A. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann. Rheum. Dis. 61 (2002) 822-825
73. Kapral T., Aletaha D., Stamm T.A., Machold K.P., and Smolen J.S. Re-employment of methotrexate in rheumatoid arthritis (RA). Effectiveness after failure of a previous course. Arthritis Rheum. 50 (2004) S552
74. Gomez-Puerta J.A., Rodriguez-Cros J.R., Graell E., Canete J.D., Albaladejo C., and Sanmarti R. One-year efficacy of etanercept in rheumatoid arthritis patients who previously failed to infliximab. Arthritis Rheum. 50 (2004) S190
75. van Vollenhoven R.F., Brannemark S., and Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann. Rheum. Dis. 63 (2004) 426-430
76. Bombardieri S., Tzioufas A.G., McKenna F., Michel B.A., Webber D.G., and Kupper H. Efficacy evaluation of adalimumab (HUMIRA) in patients with single and multiple prior biologics in the ReAct trial. Arthritis Rheum. 50 (2004) S187
77. Keystone E.C., Perruquet J.L., Lidman R.W., Stein B., Peller J.S., and Xia H.A. Switching anti-TNF therapy: real-world outcome of patients with rheumatoid arthritis who failed either infliximab or etanercept treatment and switched to another anti-TNF inhibitor. Arthritis Rheum. 50 (2004) S400-S401
78. van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. 62 (2003) 1195-1198
79. Wick M.C., Ernestam S., Lindblad S., Bratt J., Klareskog L., and van Vollenhoven R.F. Adalimumab restores clinical response in patients with secondary failure to infliximab or etanercept: results from the STURE registry at Karolinska University Hospital. Arthritis Rheum. 50 (2004) S393-S394
80. Ang H.T., and Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?. J. Rheumatol. 30 (2003) 2315-2318
81. Cohen J.D., Zaltni S., Kaiser M.J., Bozonnat M.C., Jorgensen C., Daures J.P., et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann. Rheum. Dis. 63 (2004) 209-210
82. Brocq O., Plubel Y., Breuil V., Grisot C., Flory P., Mousnier A., et al. Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med. 31 (2002) 1836-1839
83. Brocq O., Albert C., Roux C., Gerard D., Breuil V., and Ziegler L.E. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine 71 (2004) 601-603
84. Hansen K.E., Hildebrand J.P., Genovese M.C., Cush J.J., Patel S., Cooley D.A., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. 31 (2004) 1098-1102
85. Haraoui B., Keystone E.C., Thorne J.C., Pope J.E., Chen I., Asare C.G., et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. 31 (2004) 2356-2359
86. Schiff M.H., Weisman M.H., Cohen S.B., Kavanaugh A.F., Spencer-Green G.T., Perez J.L., et al. Significant clinical improvement at 6 months are sustained over 4 years in patients with rheumatoid arthritis treated with adalimumab (HUMIRA) plus methotrexate. Arthritis Rheum. 50 (2004) S182-S183
87. Durieux P., Ravaud P., Dosquet P., and Durocher A. Mise en œuvre des recommandations médicales : revue systématique des revues systématiques. Gastroenterol. Clin. Biol. 24 (2000) 1018-1025 [Effectiveness of clinical guideline implementation strategies: systematic review of systematic reviews]
88. Smolen J.S., Breedveld F.C., Burmester G.R., Combe B., Emery P., Kalden J.R., et al. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann. Rheum. Dis. 59 (2000) 504-505